The Failure of Solanezumab — How the FDA Saved Taxpayers Billions

The November 2016 announcement that Eli Lilly's investigational drug solanezumab failed in a phase 3 clinical trial dashed hopes that it would be a long-anticipated disease-modifying treatment for Alzheimer's disease. For people living with Alzheimer's — along with their relatives and caregivers,…

from #MedicinebyAlexandrosSfakianakis via xlomafota13 on Inoreader http://ift.tt/2pAGX3l
via IFTTT